Silence Therapeutics opened lower at $19.76, compared with its previous close of $19.77. In the last trading session, the stock traded between $19.76 and $19.82. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Silence Therapeutics is now worth
$ 85.32
Resulting in a loss of
$ 14.68 (14.68%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
+$0.03 (+0.13%)
Day High
$19.82
Day Low
$19.76
Day Open
$19.76
Prev Close
$19.77
Volume
6,25,685
1W Return
0.00%
1M Return
104.79%
3M Return
34.65%
6M Return
176.08%
1Y Return
194.57%
Market Cap ($ Mn)
1,192
PE Ratio
-
PB Ratio
16.48
PEG Ratio
-
ROE
-175.96%
ROCE
-61.42%
EPS (TTM)
$-0.09
1 Week
0.00%
1 Month
104.79%
3 Months
34.65%
6 Months
176.08%
9 Months
357.16%
Silence Therapeutics Q3 Results: Loss widens to $(0.24), misses estimate
Silence Therapeutics reported a Q3 loss per share of $(0.24). The result missed the analyst consensus estimate of $(0.12) by 100 percent. Losses narrowed from $(0.45) per share in the same period last year.
TodaySilence Therapeutics stock jumps 126% on $1.3bn Merck deal
Silence Therapeutics shares rose 126% after Merck KGaA agreed to acquire the firm for $1.3bn. The deal values each ADS at $20.00, a 130% premium to the October 16 closing price. Law firms Halper Sadeh and Kahn Swick & Foti are investigating the adequacy of the sale price. Completion is expected in Q1 2027, subject to regulatory and shareholder approvals.
22 days agoSilence Therapeutics closes $201.3 million upsized ADS offering
Silence Therapeutics has completed its $201.3 million public offering of ADSs at $13.50 each, following the full exercise of the underwriters' over-allotment option. The deal raises significant capital for the clinical-stage biotech firm's pipeline development, managed by Jefferies, Morgan Stanley, Cantor Fitzgerald, and William Blair. The offering was filed under SEC Form S-3 and targets qualified investors in the EEA and UK.
3mo agoSilence Therapeutics stock surges on divesiran trial success
Silence Therapeutics reported positive Phase 2 results for divesiran in polycythemia vera, showing an 88% response rate versus 19% for placebo. The stock surged to a 52-week high as the company outlined plans for Phase 3 trials in early 2027, supported by $72.1 million in cash.
3mo agoSilence Therapeutics Q2 EPS of $(0.09) beats $(0.15) estimate
Silence Therapeutics beat Q2 EPS estimates with a loss of $(0.09) per share versus $(0.15) expected. Net loss narrowed to $12.3M, supported by lower R&D expenses and strong liquidity.
3mo agoCantor Fitzgerald sees 160% upside in Silence Therapeutics
Cantor Fitzgerald initiated coverage of Silence Therapeutics Plc with an Overweight rating, projecting over 160% valuation upside based on the upcoming Phase 2 SANRECO trial results for divesiran in polycythemia vera patients. The analyst highlights the drug's dosing convenience advantage over competitors like rusfertide and assigns a 75% probability of success to the trial.
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Silence Therapeutics is now worth
$ 85.32
Resulting in a loss of
$ 14.68 (14.68%)
Note: Past profits do not guarantee future returns.
